Literature DB >> 1084799

Hepatitis B antigen, antigen subtypes, and hepatitis B antibody in normal subjects and patients with liver disease.

K Nishioka, A G Levin, M J Simons.   

Abstract

The relative sensitivities of counterimmunoelectrophoresis (CIE) and haemagglutination assays for the detection of hepatitis B surface antigen (HB(s)Ag) and antibodies (anti-HB(s)) were compared. Twelve scientists from ten countries in Asia, Africa and the Pacific region participated in the study. The participants provided serum samples from 15 953 subjects comprising patients with acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), as well as blood donors and other normal individuals. For the detection of HB(s)Ag in a reference panel serum, immune adherence haemagglutination (IAHA) was slightly more sensitive than passive haemagglutination inhibition (PHI); CIE was the least sensitive. Mean HB(s)Ag frequencies in patients with acute hepatitis, chronic hepatitis, cirrhosis, and HCC were significantly higher than in healthy controls. Passive haemagglutination (PHA) was more sensitive than CIE for the detection of anti-HB(s). The frequency of anti-HB(s) in patients with HCC was significantly lower than that in the other groups. Mean anti-HB(s) frequencies in patients with acute hepatitis, chronic hepatitis, and cirrhosis were not significantly different from that in normal subjects. Subtyping of HB(s)Ag was performed by PHI. Among asymptomatic carriers the predominant HB(s)Ag subtype in northeast Asia was adr.In India, ayw predominated in carriers, with the demarcation between adr and ayw occurring west of Burma. In West Africa the only subtype detected was ayw, but in East Africa the majority subtype was adw. The r subtype was found only in Asian populations east of India and in Western Pacific populations. In Papua New Guinea all four subtypes were identified. With one possible exception, the subtypes of HB(s)Ag-positive patients with liver disease reflected the predominant type in each geographic location.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1084799      PMCID: PMC2366375     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis.

Authors:  M E Bayer; B S Blumberg; B Werner
Journal:  Nature       Date:  1968-06-15       Impact factor: 49.962

2.  Geographical distribution of Australia antigen determinants d, y and w.

Authors:  S Mazzur; S Burgert; B S Blumberg
Journal:  Nature       Date:  1974-01-04       Impact factor: 49.962

3.  Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma.

Authors:  J B Smith; B S Blumberg
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

4.  Haemagglutination inhibition assay of the common determinants and subspecificities of Australia antigen.

Authors:  M Imai; Y Yamashita; Y Miyakawa; M Mayumi
Journal:  Immunology       Date:  1974-11       Impact factor: 7.397

  4 in total
  16 in total

Review 1.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

2.  The relationship of hepatocellular carcinoma and liver cirrhosis to hepatitis B virus infection in the Philippines.

Authors:  A L Lingao
Journal:  Gastroenterol Jpn       Date:  1989-08

3.  Mother to child transmission of hepatitis B virus in the Philippines.

Authors:  A L Lingao; N T Torres; N Muñoz; M A Lansang; S K West; F X Bosch; E O Domingo
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

4.  Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

5.  Hepatitis B virus markers in Japanese immigrants and their descendants in Bolivia and native Bolivians.

Authors:  H Sugimura; S Tsugane; S Watanabe; S Nanri; H Ishii
Journal:  Gastroenterol Jpn       Date:  1990-06

6.  Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea.

Authors:  Si Hyun Bae; Seung Kew Yoon; Jeong Won Jang; Chang Wook Kim; Soon Woo Nam; Jong Young Choi; Boo Sung Kim; Young Min Park; Seiji Suzuki; Fuminaka Sugauchi; Masashi Mizokami
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

Review 7.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

8.  Prevalence of markers of hepatitis B virus infection in various countries: a WHO collaborative study.

Authors:  O Sobĕslavský
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

9.  The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw.

Authors:  Y Ono; H Onda; R Sasada; K Igarashi; Y Sugino; K Nishioka
Journal:  Nucleic Acids Res       Date:  1983-03-25       Impact factor: 16.971

10.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study.

Authors:  Dimitrios Trichopoulos; Christina Bamia; Pagona Lagiou; Veronika Fedirko; Elisabeth Trepo; Mazda Jenab; Tobias Pischon; Ute Nöthlings; Kim Overved; Anne Tjønneland; Malene Outzen; Francoise Clavel-Chapelon; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Krasimira Aleksandrova; Vassiliki Benetou; Dimosthenis Zylis; Domenico Palli; Valeria Pala; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; H Bas Bueno-De-Mesquita; Henk J Van Kranen; Petra H M Peeters; Eiliv Lund; J Ramón Quirós; Carlos A González; Maria-Jose Sanchez Perez; Carmen Navarro; Miren Dorronsoro; Aurelio Barricarte; Björn Lindkvist; Sara Regnér; Mårten Werner; Göran Hallmans; Kay-Tee Khaw; Nick Wareham; Timothy Key; Isabelle Romieu; Shu-Chun Chuang; Neil Murphy; Paolo Boffetta; Antonia Trichopoulou; Elio Riboli
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.